“Systemic Strategy at the Patient's Service”: A Congress Report on Supportive Care in Oncology

Peterson D.E. , Boers-Doets C.B. , Bensadoun R.J. . Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015; 26(Suppl 5): v139–v151.

Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4): 277–284.

Sheibani K.M. , Mafi A.R. , Moghaddam S. . Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J Clin Oncol. 2015; 11(1): 22–27.

Lalla R.V. , Bowen J. , Barasch A. . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120(10): 1453–1461.

Lalla R.V. , Choquette L.E. , Curley K.F. . Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014; 50(11): 1098–1103.

Leenstra J.L. , Miller R.C. , Qin R. . Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014; 32(15): 1571–1577.

Sarvizadeh M. , Hemati S. , Meidani M. . Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. Adv Biomed Res. 2015; 4: 44.

Kataoka T. , Kiyota N. , Shimada T. . Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx. 2016; 43(6): 677–684.

Giralt J. , Tao Y. , Bensadoun R.J. . Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: a phase II randomized trial. J Clin Oncol. 2015; 33(15 Suppl): 6058.

Orvain C. , Moles-Moreau M.P. , Francois S. . Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis. Support Care Cancer. 2015; 23(2): 359–364.

Tsujimoto T. , Yamamoto Y. , Wasa M. . L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015; 33(1): 33–39.

Rugo H.S. , Seneviratne L. , Beck J.T. . Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017; 18(5): 654–662.

Lindley C. , McCune J.S. , Thomason T.E. . Perception of chemotherapy side effects cancer versus non cancer patients. Cancer Pract. 1999; 7: 59–65.

Navari R.M. , Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016; 374(14): 1356–1367.

Wickham R. Best practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for use. J Support Oncol. 2010; 8: 10–15.

MASCC/ESMO Antiemetic guidelines 2016 v.1.2. Available from http://www.mascc.org/antiemetic-guidelines.

Stathis M. , Pietra C. , Rojas C. , Slusher B.S. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012; 689(1–3): 25–30.

Rojas C. , Slusher B.S. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (netupitant/palonosetron). Cancer Treat Rev. 2015; 41: 904–913.

Chasen M.R. , Rapoport B.L. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence. Future Oncol. 2016; 12: 763–778.

Navari R.M. , Qin R. , Ruddy K.J. . Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016; 375: 134–142.

Aapro M. , Molassiotis A. , Dicato M. . The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012; 23: 1986–1992.

Wood K.E. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002; 121: 877–905.

Torbicki A. , van Beek E.J.R. , Charbonnier B. . Linee guida per la diagnosi ed il trattamento dell'embolia polmonare acuta. Ital Heart J Suppl. 2001; 2: 161–199.

Blom J.W. , Doggen C.J. , Osanto S. , Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715–722.

Kroger K. , Weiland D. , Ose C. . Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006; 17: 297–303.

Al-Shamsi H.O. , Al Farsi A. , Anjum M. . Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. J Gastrointest Oncol. 2015; 6(3): 274–279.

Petrelli F. , Cabiddu M. , Borgonovo K. , Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012; 23: 1672–1679.

Saphner T. , Tormey D.C. , Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9: 286–294.

Agnelli G. , Gussoni G. , Bianchini C. . Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10: 943–949.

Khorana A. , Kuderer N.M. , Culakova E. , Lyman G.H. , Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902–4907.

Verso M. , Agnelli G. , Barni S. , Gasparini G. , LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012; 7: 291–292.

Mandala M. , Falanga A. , Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011; 22(Suppl 6): vi85–vi92.

Lee A. , Levine M.N. , Baker Rl . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. NEJM. 2003; 349: 146–153.

Prins M.H. , Lensing A.W. , Bauersachs R. . Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb Res. 2013; 11: 21.

van der Hulle T. , den Exter P.L. , Kooiman J. , van der Hoeven J.J. , Huisman M.V. , Klok F.A. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost. 2014; 12(7): 1116–1120.

Platania M. , Verzoni E. , Vitali M. Hyponatremia in cancer patients. Tumori. 2015; 101: 246–248.

Renneboog B. , Musch W. , Vandemergel X. , Manto M.U. , Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006; 119(1): 71.e1–8.

Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007; 15(12): 1341–1347.

Berardi R. , Santoni M. , Rinaldi S. , Nunzi E. , Smerilli A. , Caramanti M. Risk of hyponatraemia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials. PLoS One. 2016; 11(5): e0152079.

Barnard Z.R. , Walcott B.P. , Kahle K.T. , Nahed B.V. , Coumans J.V. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol. 2012; 29(1): 374–377.

Berghmans T. , Paesmans M. , Body J.J. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer. 2000; 8(3): 192–197.

Abu Zeinah G.F. , Al-Kindi S.G. , Hassan A.A. , Allam A. Hyponatraemia in cancer: association with type of cancer and mortality. Eur J Cancer Care. 2015; 24(2): 224–231.

Doshi S.M. , Shah P. , Lei X. , Lahoti A. , Salahudeen A.K. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012; 59(2): 222–228.

Castillo J.J. , Vincent M. , Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6): 756–765.

Agustoni F. , Fucà G. , Corrao G. . Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan. Ann Oncol. 2016; 27: 1469P.

Corona G. , Giuliani C. , Verbalis J.G. , Forti G. , Maggi M. , Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. PLoS One. 2015; 10(4): e0124105.

Berardi R. , Santoni M. , Newsom-Davis T. . Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget. 2017; 8(14): 23871–23879.

Balachandran K. , Okines A. , Gunapala R. , Morganstein D. , Popat S. Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer. 2015; 15: 163.

Adrogue H.J. , Madias N.E. Hyponatremia. N Engl J Med. 2000; 342(21): 1581–1589.

Schrier R.W. , Gross P. , Gheorghiade M. ; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099–2112.

Verbalis J.G. , Adler S. , Schrier R.W. , Berl T. , Zhao Q. , Czerwiec F.S. ; SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol. 2011; 164(5): 725–732.

De las Penas R. , Escobar Y. , Henao F. , Blasco A. , Rodríguez C.A. Spanish Society for Medical Oncology: SEOM guidelines on hydroelectrolytic disorders. Clin Transl Oncol. 2014; 16(12): 1051–1059.

Jensen G.L. , Mirtallo J. , Compher C. . Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr. 2010; 34(2): 156–159.

Cao D.X. , Wu G.H. , Zhang B. . Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr. 2010; 29(1): 72–77.

Hebuterne X. , Lemarié E. , Michallet M. , de Montreuil C.B. , Schneider S.M. , Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014; 38(2): 196–204.

Andreyev H.J. , Norman A.R. , Oates J. , Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998; 34(4): 503–509.

Dewys W.D. , Begg C. , Lavin P.T. . Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980; 69(4): 491–497.

Klein S. , Kinney J. , Jeejeebhoy K. . Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr. 1997; 66(3): 683–706.

Klute K.A. , Brouwer J. , Jhawer M. . Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: a multicentre analysis. Eur J Cancer. 2016; 63: 189–200.

Cox S. , Powell C. , Carter B. , Hurt C. , Mukherjee S. , Crosby T.D. Role of nutritional status and intervention in oesophageal cancer treated with definitive chemoradiotherapy: outcomes from SC0PE1. Br J Cancer. 2016; 115(2): 172–177.

Daly L.E. , Power D.G. , O'Reilly Á . The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017; 116(3): 310–317.

Martin L. , Senesse P. , Gioulbasanis I. . Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015; 33(1): 90–99.

Arends J. , Bachmann P. , Baracos V. . ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017; 36(1): 11–48.

Stratton R.J. , King C.L. , Stroud M.A. , Jackson A.A. , Elia M. ‘Malnutrition Universal Screening Tool’ predicts mortality and length of hospital stay in acutely ill elderly. Br J Nutr. 2006; 95(2): 325–330.

White J.V. , Guenter P. , Jensen G. , Malone A. , Schofield M. ; Academy Malnutrition Work Group; A.S.P.E.N. Malnutrition Task Force; A.S.P.E.N. Board of Directors. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr. 2012; 36(3): 275–283.

Stratton R.J. , Elia M. Encouraging appropriate, evidence-based use of oral nutritional supplements. Proc Nutr Soc. 2010; 69(4): 477–487.

Hubbard G.P. , Elia M. , Holdoway A. , Stratton R.J. A systematic review of compliance to oral nutritional supplements. Clin Nutr. 2012; 31(3): 293–312.

Baldwin C. , Spiro A. , Ahern R. , Emery P.W. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104(5): 371–385.

Spiro A. , Baldwin C. , Patterson A. , Thomas J. , Andreyev H.J. The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Br J Cancer. 2006; 95(4): 431–434.

Vogler B.K. , Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract. 1999; 49: 823–828.

Vernieri C. , Casola S. , Foiani M. , Pietrantonio F. , de Braud F. , Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discov. 2016; 6: 1315–1333.

Golden E.B. , Lam P.Y. , Kardosh A. . Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009; 113: 5927–5937.

Wang Y.M. , Jin B.Z. , Ai F. . The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012; 69(5): 1213–1220.

Scher H.I. , Jia X. , Chi K. . Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011; 29(16): 2191–2198.

Sanchez-Lara K. , Turcott J.G. , Juárez-Hernández E. . Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. Clin Nutr. 2014; 33: 1017–1023.

Daenen L.G. , Cirkel G.A. , Houthuijzen J.M. . Increased plasma levels of chemoresistance-inducing fatty acid 16: 4(n-3) after consumption of fish and fish oil. JAMA Oncol. 2015; 1(3): 350–358.

Lee C. , Raffaghello L. , Brandhorst S. . Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012; 4: 124–127.